FDA News Release—On April 16, saying that alternative monoclonal antibody therapies authorized to treat patients with COVID-19 remain available, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and…
Search results for: hospital
Rheum After 5: Dr. Stuart Kassan, Golf Enthusiast
About 10 years ago, Stuart S. Kassan, MD, FACP, MACR, was playing in a local golf tournament at the Denver Country Club. Each player had to tee off over a water hole in front of roughly 100 club members. His ball was the only one that landed in the water—twice. He was introduced to golf…
Late Spring 2021’s Awards, Appointments & Announcements in Rheumatology
AMA Honors Mark Andrejeski with Lifetime Achievement Award In November 2020, the American Medical Association (AMA) presented Mark Andrejeski, the recently retired executive vice president of the ACR, with its Medical Executive Lifetime Achievement Award. The award honors a medical association executive who has contributed substantially to the goals and ideals of the medical profession….
Case Report: Rapidly Progressive Interstitial Lung Disease in a 6-Year-Old
Clinically amyopathic dermatomyositis (CADM), a rare subset of dermatomyositis (DM), is an autoimmune disease characterized by cutaneous findings of typical DM without evidence of myositis. Childhood presentation of CADM is rare, and not many studies describe the epidemiology of juvenile CADM.1,2 Although lung disease is rare among patients with juvenile DM, a few reports have…
A Team Approach Improves the Transition from Pediatric to Adult Care
Nearly all adolescents and young adults (AYAs) with chronic pediatric rheumatic disease require transfer of care to an adult rheumatologist, yet almost half are lost from care at the time of transfer.1-3 Although sometimes framed as a discrete event, transition refers to the longitudinal process, often spanning several years, in which AYAs and their families…
ACR, Ophthalmologists & Dermatologists Issue Joint Hydroxychloroquine Statement
Since 1991, hydroxychloroquine (HCQ) has been a staple for the treatment of patients with systemic lupus erythematosus; it has been shown to improve survival, reduce cardiovascular risk, thrombosis and renal damage, delay or prevent lupus cerebritis and more. However, HCQ can potentially bind in the retinal pigment epithelium and cause degeneration of photoreceptors, leading to…
COPA Syndrome: What Do We Know About This Rare Disease?
ACR CONVERGENCE 2020—Tiphanie Phillips Vogel, MD, PhD, assistant professor of pediatrics and internal medicine at Baylor College of Medicine, Houston, moderated the session on COPA syndrome, which drew 324 attendees on a Sunday morning. This rare genetic cause of immune dysregulation can present like anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, lupus, lupus nephritis or rheumatoid…
Months After COVID-19 Infection, Rheumatic-Like Symptoms Persist
As more people get vaccinated for COVID-19, there’s hope that the long days of a pandemic, which has claimed more than 2.5 million lives globally and 500,000 in the U.S., will soon draw to a close and allow daily life to return to normal. However, for some people, this recovery may take longer, because the…
Virtual Advocacy Saves Time, Extends Reach
As a member of the ACR Government Affairs Committee, Mohammad Kamran, MD, has embraced virtual advocacy as a way to make a difference for patients during the COVID-19 pandemic and beyond.
14 Rheumatology Treatments Make Top 50 List of Drugs That Can Cause Anaphylaxis
A recent study of data from the FDA’s Adverse Event Reporting System reveals that 14 drugs commonly prescribed by rheumatologists are on the list of the top 50 drugs that can cause anaphylaxis.
- « Previous Page
- 1
- …
- 68
- 69
- 70
- 71
- 72
- …
- 320
- Next Page »